

## **A promising advance in the treatment of neurological diseases: Ceres Brain Therapeutics raises over €6 million**

**Ceres announces a new round of funding of over €6 million to support the clinical development of innovative treatments in neurology.**

Paris, 22 January 2024 - Ceres Brain Therapeutics, a biotechnology company specialising in the development of cutting-edge treatments for neurological diseases and led by Dr. Thomas Joudinaud, announces that it has raised over €6 million, with the participation of ANJAC, a French family-owned industrial group and preferred partner of healthcare laboratories and beauty and well-being brands, as well as its existing shareholders. The funds raised will support the entry into the clinical phase of CBT101, the company's most advanced development.

A spin-off from the French Atomic Energy Commission (CEA), Ceres Brain Therapeutics is committed to researching and developing innovative solutions to treat neurological diseases. Its lead product, CBT101, is a drug in development designed to treat neuronal metabolic defects associated with major neurological diseases, such as:

- Creatine transporter deficiency syndrome (c. 16,000 patients worldwide).
- Amyotrophic lateral sclerosis (ALS) or Charcot's disease (c. 40,000 patients in Europe and the United States).
- Parkinson's disease (c. 10 million patients).

Ceres Brain Therapeutics is the only company capable of delivering creatine, a natural compound with metabolic properties essential to brain cell function, directly to brain neurons.

In addition to CBT101, the company is also developing other preclinical programs, including CBT201, for the treatment of tauopathies, and CBT301, a therapeutic antibody targeting brain tumors.

### **Strategic financial support to advance the clinical programme**

The fundraising, carried out in October 2024 with the support of Bucéphale Finance (Julien Durand) and Axiptiter (Constance le Vert), will enable Ceres Brain Therapeutics to strengthen its research team, particularly in the field of ALS, and expand its management team to prepare for strategic partnerships. This strategic financial support will enable Ceres Brain Therapeutics to continue the studies required for the clinical development of CBT101 and to extend the scope of its research into other key therapeutic areas.

Thomas Joudinaud said: *"I am delighted to welcome ANJAC as a shareholder in Ceres Brain Therapeutics. We share a common and ambitious vision of future treatments for neurological diseases and are very enthusiastic about Ceres' ability to develop innovative therapeutic treatments. The significant reinvestment of the historical shareholders is proof of their renewed confidence in this venture, and the entire Ceres team thanks them warmly"*.

Aurélien Chaufour, Chairman of the ANJAC Group, added: *"We are very enthusiastic about the idea of supporting this project, financially, scientifically and industrially. It's an exciting and truly visionary initiative"*.

## **About Ceres Brain Therapeutics**

A spin-off from the French Atomic Energy Commission (CEA), Ceres specialises in the research and development of treatments for neurological diseases. Ceres' mission is to respond to unmet needs in this complex field. With an innovative approach and major funding, Ceres strives to push back the boundaries of science to offer new therapeutic perspectives to patients.

**[www.ceres-brain.com](http://www.ceres-brain.com)**

## **About the ANJAC Health & Beauty Group**

The French industrial group ANJAC Health & Beauty is a partner to pharmaceutical laboratories and cosmetics and well-being brands. It creates, develops and manufactures, from raw materials to finished products. It comprises 16 expert, complementary companies and 22 R&D and production sites in the health, beauty and dietary supplements sectors: Aircos-Pascual, Apollo, APR Beauty, Chemineau, Cosmetix West, Eurowipes, Feltor, Innovi, LPEV, Pillar5 Pharma, Roval, Shadeline, Sicaf and Stephid. Founded in 2008, the Group now employs more than 3,200 people and will achieve sales of nearly €800 million by 2024.

## **contacts**

### Ceres Brain Therapeutics

Vae Solis Communications

Asmae Benfella [Asmae.benfella@vae-solis.com](mailto:Asmae.benfella@vae-solis.com) // 06 63 30 86 41

### ANJAC Health & Beauty

Citigate Agency Dewe Rogerson x Grayling

Manuel Chaplet [manuel.chaplet@grayling.com](mailto:manuel.chaplet@grayling.com) // 06 35 09 27 54

Nicolas Bammez [Nicolas.bammez@grayling.com](mailto:Nicolas.bammez@grayling.com) // 06 64 37 93 97